126 related articles for article (PubMed ID: 16572842)
1. [Acute toxicity and immunoprotection of recombinant apxI toxin of Actinobacillus pleuropneumoniae in mice].
Yan KX; Liu JJ; Zhou R; Wu B; Liu WH; Chen HC
Sheng Wu Gong Cheng Xue Bao; 2006 Jan; 22(1):65-70. PubMed ID: 16572842
[TBL] [Abstract][Full Text] [Related]
2. [Cloning and expression of hemolytic-toxin from Actinobacillus pleuropneumoniae and the immunoprotection in mice].
Du A; Diao Y; Zhang W; Zhang R; Zang D; Liu F
Wei Sheng Wu Xue Bao; 2008 Mar; 48(3):342-8. PubMed ID: 18479061
[TBL] [Abstract][Full Text] [Related]
3. [Study on immunogenicity of the N-terminal polypeptide of RTX toxin I of Actinobacillus pleuropneumoniae].
Mei L; Zhou R; Lu HS; Bei WC; Liu WH; Lin LW; Hong WZ; Chen HC
Sheng Wu Gong Cheng Xue Bao; 2006 Jan; 22(1):39-45. PubMed ID: 16572838
[TBL] [Abstract][Full Text] [Related]
4. Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA.
Shin SJ; Bae JL; Cho YW; Lee DY; Kim DH; Yang MS; Jang YS; Yoo HS
FEMS Immunol Med Microbiol; 2005 Feb; 43(2):155-64. PubMed ID: 15681145
[TBL] [Abstract][Full Text] [Related]
5. [Construction and immunogenicity of an attenuated mutant of Actinobacillus pleuropneumoniae by insertional inactivation of apxIC].
Xu FZ; Shi AH; Chen XL; Yang B; Wang JL
Wei Sheng Wu Xue Bao; 2007 Oct; 47(5):923-7. PubMed ID: 18062275
[TBL] [Abstract][Full Text] [Related]
6. Nasal immunization with major epitope-containing ApxIIA toxin fragment induces protective immunity against challenge infection with Actinobacillus pleuropneumoniae in a murine model.
Seo KW; Kim SH; Park J; Son Y; Yoo HS; Lee KY; Jang YS
Vet Immunol Immunopathol; 2013 Jan; 151(1-2):102-12. PubMed ID: 23200821
[TBL] [Abstract][Full Text] [Related]
7. Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae.
Xu F; Chen X; Shi A; Yang B; Wang J; Li Y; Guo X; Blackall PJ; Yang H
Vet Microbiol; 2006 Dec; 118(3-4):230-9. PubMed ID: 16930871
[TBL] [Abstract][Full Text] [Related]
8. Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria.
Lee KY; Kim DH; Kang TJ; Kim J; Chung GH; Yoo HS; Arntzen CJ; Yang MS; Jang YS
FEMS Immunol Med Microbiol; 2006 Dec; 48(3):381-9. PubMed ID: 17054716
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of a live, attenuated apxIICA inactivation mutant of Actinobacillus pleuropneumoniae lacking a drug resistance marker.
Bei W; He Q; Yan L; Fang L; Tan Y; Xiao S; Zhou R; Jin M; Guo A; Lv J; Huang H; Chen H
FEMS Microbiol Lett; 2005 Feb; 243(1):21-7. PubMed ID: 15667996
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model.
Chiang CH; Huang WF; Huang LP; Lin SF; Yang WJ
Vaccine; 2009 Jul; 27(34):4565-70. PubMed ID: 19520199
[TBL] [Abstract][Full Text] [Related]
11. Potential use an Actinobacillus pleuropneumoniae double mutant strain DeltaapxIICDeltaapxIVA as live vaccine that allows serological differentiation between vaccinated and infected animals.
Liu J; Chen X; Lin L; Tan C; Chen Y; Guo Y; Jin M; Guo A; Bei W; Chen H
Vaccine; 2007 Nov; 25(44):7696-705. PubMed ID: 17767980
[TBL] [Abstract][Full Text] [Related]
12. Development of
Jung M; Won H; Shin MK; Oh MW; Shim S; Yoon I; Yoo HS
J Vet Sci; 2019 Mar; 20(2):e2. PubMed ID: 30944525
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drug resistance marker in the pigs.
Bei W; He Q; Zhou R; Yan L; Huang H; Chen H
Vet Microbiol; 2007 Nov; 125(1-2):120-7. PubMed ID: 17580102
[TBL] [Abstract][Full Text] [Related]
14. The N-terminal domain of RTX toxin ApxI of Actinobacillus pleuropneumoniae elicits protective immunity in mice.
Seah JN; Frey J; Kwang J
Infect Immun; 2002 Nov; 70(11):6464-7. PubMed ID: 12379729
[TBL] [Abstract][Full Text] [Related]
15. Positive role for rApxIVN in the immune protection of pigs against infection by Actinobacillus pleuropneumoniae.
Wang C; Wang Y; Shao M; Si W; Liu H; Chang Y; Peng W; Kong X; Liu S
Vaccine; 2009 Sep; 27(42):5816-21. PubMed ID: 19654060
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of multicomponent recombinant vaccines against Actinobacillus pleuropneumoniae in mice.
Shao M; Wang Y; Wang C; Guo Y; Peng Y; Liu J; Li G; Liu H; Liu S
Acta Vet Scand; 2010 Sep; 52(1):52. PubMed ID: 20831818
[TBL] [Abstract][Full Text] [Related]
17. Recombinant ApxIV protein enhances protective efficacy against Actinobacillus pleuropneumoniae in mice and pigs.
Wu HC; Yeh PH; Hsueh KJ; Yang WJ; Chu CY
J Appl Microbiol; 2018 Jun; 124(6):1366-1376. PubMed ID: 29431246
[TBL] [Abstract][Full Text] [Related]
18. Selection of serotype-specific vaccine candidate genes in Actinobacillus pleuropneumoniae and heterologous immunization with Propionibacterium acnes.
Lei L; Sun C; Lu S; Feng X; Wang J; Han W
Vaccine; 2008 Nov; 26(49):6274-80. PubMed ID: 18835316
[TBL] [Abstract][Full Text] [Related]
19. Construction and immunogencity of a DeltaapxIC/DeltaapxIIC double mutant of Actinobacillus pleuropneumoniae serovar 1.
Lin L; Bei W; Sha Y; Liu J; Guo Y; Liu W; Tu S; He Q; Chen H
FEMS Microbiol Lett; 2007 Sep; 274(1):55-62. PubMed ID: 17608699
[TBL] [Abstract][Full Text] [Related]
20. Characterization of antigenic determinants in ApxIIA exotoxin capable of inducing protective immunity to Actinobacillus pleuropneumoniae challenge.
Seo KW; Kim DH; Kim AH; Yoo HS; Lee KY; Jang YS
Immunol Invest; 2011; 40(5):465-80. PubMed ID: 21425909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
